Leerink analyst Ami Fadia raised her price target for Heron Therapeutics (HRTX) to $29 from $27 after Tesaro (TSRO) announced earlier this week that it has withdrawn all promotional support for IV Varubi, based on numerous reports of anaphylaxis. Heron's Cinvanti, Tesaro's Varubi and Merck's (MRK) Emend are the only three branded NK-1 antagonists in the market today for chemo induced nausea and vomiting, Fadia tells investors in a research note. With Emend expected to go generic soon, Cinvanti will be the sole marketed branded agent, the analyst adds. She increased her 2023 estimate for Cinvanti from $150M to just under $200M and keeps an Outperform rating on Heron Therapeutics. The analyst continues to see upside for the stock ahead of the two Phase 3 trials for HTX-011 expected to read out in Q2.